Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | HAVCR2 | Q8TDQ0 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13273862 | 0.76 | MAPT (0.63) | MAPTTP53POLBHAVCR2RAB9A | |
| SCHEMBL20143373 | 0.74 | ALDH1A1 (0.62) | MAPTPOLBMGLLRAB9ALMNA | |
| SCHEMBL8268112 | 0.73 | MAPT (0.60) | MAPTTP53POLBHAVCR2RAB9A | |
| SCHEMBL7056553 | 0.73 | TP53 (0.66) | MAPTTP53POLBHAVCR2RAB9A | |
| SCHEMBL7059963 | 0.73 | MAPT (0.53) | MAPTTP53POLBHAVCR2RAB9A | |
| SCHEMBL7295341 | 0.73 | SPHK2 (0.59) | MAPTTP53RAB9AMAPK1NPC1 | |
| SCHEMBL6565112 | 0.73 | L3MBTL1 (0.59) | MAPTTP53POLBL3MBTL1FFAR4 | |
| SCHEMBL6985892 | 0.73 | L3MBTL1 (0.59) | MAPTTP53POLBRAB9AMAPK1 | |
| SCHEMBL27612413 | 0.72 | L3MBTL1 (0.62) | MAPTTP53POLBHAVCR2RAB9A | |
| SCHEMBL12747582 | 0.72 | L3MBTL1 (0.62) | MAPTTP53POLBRAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | MAPT 2401/4885TP53 4477/4885POLB 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.